Evaluation of Cladribine treatment in refractory celiac disease type Ⅱ
Evaluation of Cladribine treatment in refractory celiac disease type Ⅱ作者机构：Department of Gastroenterology and Hepatology VU University Medical Center Department of Gastroenterology and Hepatology St. Antonius Hospital Department of Epidemiology and Biostatistics VU University Medical Center Department of Pathology VU University Medical Center Department of Haematology VU University Medical Center
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2011年第17卷第4期
页 面：506-513页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Supported by An Unrestricted Grant from Astra Zeneca
主 题：Cladribine Refractory celiac disease Clinical course Enteropathy associated T-cell lymphoma Survival
摘 要：AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) Ⅱ. METHODS: An open-label cohort-study of RCD Ⅱ patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS: Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION: Treatment of RCD Ⅱ with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.
维普期刊数据库